Related Experiment Video
Updated: Sep 17, 2025
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Effect and safety of immune checkpoint inhibitors in metastatic lung cancer: A retrospective study
Arvind Kumar1, Arun Raja1, Dipika Narayan2
1Department of General Medicine & Medical oncology, Near Sudha Dairy, Bokaro General Hospital, Biada Housing Colony, Ritudih, Bokaro Steel City, Jharkhand - 827012, India.
Abstract:
Cancer is a major global public health issue. Immune checkpoint inhibitors are increasingly used for managing advanced malignancies. However, their effect is limited by immune-related adverse events. Hence, a retrospective, single-institutional study found a 60% clinical benefit ratio among 30 patients receiving Immune checkpoint inhibitors therapy. Nonetheless, a small sample size, patient heterogeneity and retrospective design require further validation for more conclusive results.
Insights
Immune checkpoint inhibitors show a 60% clinical benefit for advanced cancer patients. Further research is needed due to the study
Area of Science:
- Oncology
- Immunotherapy
Background:
- Cancer represents a significant global health challenge.
- Immune checkpoint inhibitors (ICIs) are vital in treating advanced cancers.
- Adverse events related to immunotherapy limit ICI efficacy.
Purpose of the Study:
- To evaluate the clinical benefit ratio of immune checkpoint inhibitors in advanced malignancies.
- To assess the safety and efficacy of ICIs in a real-world clinical setting.
Main Methods:
- Retrospective analysis of data from a single institution.
- Inclusion of 30 patients undergoing immune checkpoint inhibitor therapy.
- Assessment of clinical benefit ratio and adverse events.
Main Results:
- A 60% clinical benefit ratio was observed in patients receiving ICIs.
- The study identified the potential of ICIs in managing advanced cancers.
- Immune-related adverse events were noted as a limiting factor.
Conclusions:
- Immune checkpoint inhibitors demonstrate a notable clinical benefit in advanced malignancies.
- Limitations including small sample size and retrospective design necessitate further validation.
- Future prospective studies are required for definitive conclusions on ICI therapy.
More Related Videos
13:37A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
Published on: March 12, 2014
08:06Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
Published on: November 26, 2010
